Holen Sie sich die Stockscreener-App
4.875
0.51%
0.00
Schlusskurs vom Vortag:
$4.875
Offen:
$4.91
24-Stunden-Volumen:
520.36K
Relative Volume:
0.11
Marktkapitalisierung:
$3.40B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-4.2763
EPS:
-1.14
Netto-Cashflow:
$-425.62M
1W Leistung:
+0.62%
1M Leistung:
+38.03%
6M Leistung:
-27.99%
1J Leistung:
+31.02%
1-Tages-Spanne:
$4.8383
$5.00
1-Wochen-Bereich:
$4.43
$5.38
52-Wochen-Spanne:
$3.10
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Vergleichen Sie IBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IBRX | 4.9088 | 3.40B | 1.31M | -597.65M | -425.62M | -1.14 |
| VRTX | 445.91 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.64 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.06 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.23 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ImmunityBio Reports Third-Quarter 2024 Financial Results - The Bakersfield Californian
(IBRX) Technical Pivots with Risk Controls - Stock Traders Daily
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3%Should You Sell? - MarketBeat
Why ImmunityBio Stock Is Trading Higher Thursday - MSN
Commit To Buy ImmunityBio At $4, Earn 25% Using Options - Nasdaq
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes - Law360
Penny Stock Trades: Joby Aviation and ImmunityBio - Baystreet.ca
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6%Here's Why - MarketBeat
(IBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - TipRanks
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 - Seeking Alpha
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume – Still a Buy? - Defense World
ImmunityBio Stock Heats Up, Catches Retail's Eye On Cancer Drug Trial Progress And Analyst’s Bullish Call - Barchart
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
ImmunityBio stock jumps after trial update (IBRX:NASDAQ) - Seeking Alpha
Stock Traders Buy High Volume of ImmunityBio Call Options (NASDAQ:IBRX) - MarketBeat
EF Hutton sees over 600% upside in biotech small cap ImmunityBio - Kursiv Media
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
ImmunityBio (IBRX) Stock Extends Pre-Hour Rally Following Clinical Trial News - Stocks Telegraph
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL - Yahoo! Voices
ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL - World Pharmaceutical Frontiers
ImmunityBio (NASDAQ:IBRX) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I - Defense World
ImmunityBio (NASDAQ:IBRX) Trading 7.8% HigherHere's What Happened - MarketBeat
ImmunityBio Stock Could Rocket 800%, Analyst Says - Barron's
This Biotech Stock Could Rocket 800%, Analyst Says - MSN
ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - TipRanks
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma - Business Wire
ImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I - MarketBeat
800% Upside For This Biotech StockAnalyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat
EF Hutton sets stock target with buy rating for ImmunityBio, cites cancer therapy - Investing.com
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact L - GuruFocus.com
Layoff Tracker: Takeda Cuts More Employees, Total Exceeds 1,300 in 2024 - BioSpace
ImmunityBio to Participate in the Jefferies London Healthcare Conference - BioSpace
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):